NPM1 and acute myeloid leukemia: The new NPM1 inhibitor triggersapoptosis in AML cell lines and primary cells from AML patients andreduces tumor infiltration in a mouse model of AML with NPM1 C+ mutation.The disclosed phenotype-guided discovery of UCM-13369, a novel smallmolecule inspired on microbiota metabolites, confirms that CSC deathinduced by NPM1 inhibition represents a promising therapeutic opportunityfor NPM1-mutated AML, a high-mortality disease.